| ²é¿´: 530 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
dingjieboy½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÂÛÎÄСÐÞ£¬Éó¸åÈËÖ»ÌáÁËÒ»ÌõÐÞ¸ÄÒâ¼û£¬µ«²»Ì«ÈÝÒ×Ð޸ģ¬100½ð±ÒÇóÖú¡£
|
||
|
Ò»2Á½·Ö¶àµÄÔÓÖ¾£¬Ñо¿µÄÊÇLSD1¡¢E-cadherin¡¢N-cadherinÔÚijÖ×ÁöµÄ±í´ï¼°ÆäÁÙ´²ÒâÒå¡£Éó¸åÈËÒâ¼ûÈçÏ£ºThis study is a well done retrospective pathologic archive histologic classification of colon cancer based on LSD1 and E,N-cadherin with a concise and informative discussion of biology leading to metastasis and poor outcome. In your discussion it would be important to note that prospective study to confirm these findings while at same time using a control group compared to LSD1 treatment group would be needed to validate theories of clinical applicability!¡£ ÎÒÏë°ÑÕâµãÒâ¼û¼Óµ½ÒÔÏÂÕâ¶Î»°ÖУ¬Çó½Ì¸÷λ¸ßÈ˰ïæÐ޸쬲»Éõ¸Ðл¡£ Due to the high structural and mechanistic similarities between LSD1 and amine oxidases, monoamine oxidase (MAO) inhibitors such as pargyline, tranylcypromine and polyamine analogues have been shown to inhibit LSD1 enzymatic activity [38]. In vitro experiments, these inhibitors can inhibit LSD1 expression in cancer cells and affect a reexpression of multiple, aberrantly silenced genes important in the development of cancer [38]. Lv et al. reported that interruption of LSD1 using siRNA or pargyline could suppress proliferation, migration and invasion of non-small cell lung cancer cells [13]. Despite some good basic research results, further effort should be made to validate their clinical application value in cancer treatment. |
» ²ÂÄãϲ»¶
297Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
26µ÷¼Á 086003
ÒѾÓÐ3È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
271·ÖÇóµ÷¼ÁѧУ
ÒѾÓÐ11È˻ظ´
320·ÖÈ˹¤ÖÇÄܵ÷¼Á
ÒѾÓÐ6È˻ظ´
Çóµ÷¼Á£¬Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶
ÒѾÓÐ8È˻ظ´
280Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
Çó²ÄÁϵ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ289·Ö
ÒѾÓÐ15È˻ظ´
26¿¼Ñе÷¼Á0710 0860
ÒѾÓÐ6È˻ظ´
282Çóµ÷¼Á
ÒѾÓÐ22È˻ظ´
qfzcom
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 40
- Ó¦Öú: 34 (СѧÉú)
- ¹ó±ö: 0.062
- ½ð±Ò: 4748.6
- É¢½ð: 56
- ºì»¨: 8
- ɳ·¢: 11
- Ìû×Ó: 2122
- ÔÚÏß: 207.6Сʱ
- ³æºÅ: 2081714
- ×¢²á: 2012-10-23
- רҵ: »·¾³¹¤³Ì
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-12-05 21:10:31
dingjieboy: ½ð±Ò+20, ·ÒëEPI+1, ¡ïÓаïÖú, ¸ÐлÄúÌṩµÄ°ïÖú£¡µ«ÎÒÊÇÏë°ÑÉó¸åÈ˵ÄÒâ¼û£¨µÚÒ»¶ÎµÄºì×Ö²¿·Ö£©¼Óµ½ÎÒµÄÌÖÂÛ£¨µÚ¶þ¶ÎµÄºì×Ö²¿·Ö£¬ÉÐδÐ޸ģ©ÖÐÈ¥¡£Õâ¸öÉó¸åÈ˵ÄÒâ¼ûÒ²Óеã¹Ö£¬ÎÒ²¢Ã»ÓÐ×öµ½LSD1µÄ¸ÉԤʵÑ飬ֻÊÇ×öÁËLSD1¡¢E-cadherin¡¢N-cadherinÔڽ᳦°©±í´ïµÄ¼ì²â¡£È´ÒªÎÒÔÚÌÖÂÛ²¿·Ö¼ÓLSD1¸ÉÔ¤µÄÁÙ´²ÊµÑé½øÈ¥£¬ÊµÔÚΪÄÑ¡£ 2012-12-06 14:47:30
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-12-05 21:10:31
dingjieboy: ½ð±Ò+20, ·ÒëEPI+1, ¡ïÓаïÖú, ¸ÐлÄúÌṩµÄ°ïÖú£¡µ«ÎÒÊÇÏë°ÑÉó¸åÈ˵ÄÒâ¼û£¨µÚÒ»¶ÎµÄºì×Ö²¿·Ö£©¼Óµ½ÎÒµÄÌÖÂÛ£¨µÚ¶þ¶ÎµÄºì×Ö²¿·Ö£¬ÉÐδÐ޸ģ©ÖÐÈ¥¡£Õâ¸öÉó¸åÈ˵ÄÒâ¼ûÒ²Óеã¹Ö£¬ÎÒ²¢Ã»ÓÐ×öµ½LSD1µÄ¸ÉԤʵÑ飬ֻÊÇ×öÁËLSD1¡¢E-cadherin¡¢N-cadherinÔڽ᳦°©±í´ïµÄ¼ì²â¡£È´ÒªÎÒÔÚÌÖÂÛ²¿·Ö¼ÓLSD1¸ÉÔ¤µÄÁÙ´²ÊµÑé½øÈ¥£¬ÊµÔÚΪÄÑ¡£ 2012-12-06 14:47:30
Due to the high structural and mechanistic similarities between LSD1 and amine oxidases, monoamine oxidase (MAO) inhibitors such as pargyline, tranylcypromine and polyamine analogues have been shown to inhibit LSD1 enzymatic activity [38]. In vitro experiments these inhibitors can inhibit expression of LSD1 in cancer cells and affect a reexpression of multiple, aberrantly silenced genes important in the development of cancer [38]. Lv et al. reported that the interruption of LSD1 using siRNA or pargyline could suppress proliferation, migration and invasion of non-small cell lung cancer cells [13]. Despite some good basic research results, further efforts should be made to validate their clinical application value in cancer treatment.ÕûÌåÀ´ËµÐ´µÄ»¹¿ÉÒÔ£¬¾ÍÊÇÆäÖм¸¸öµØ·½ÉÔ΢ÐÞ¸ÄÁËһϣ¬¶¼ÊÇϸ½ÚÎÊÌ⣬ϸ½Ú¾ö¶¨³É°Ü¡£¼ÈÈ»¶¼µ½ÕâÒ»²½ÁË£¬¾ÍÈÏÕæÐÞ¸Äһϡ£ËµÊµ»°£¬Ð´µÄ²»´í£¬¼ÓÓÍ¡£ |
2Â¥2012-12-05 19:04:52














»Ø¸´´ËÂ¥
10